CMS Issues Proposed Rule to Cover ‘Breakthrough’ Medical Devices

News
Published on:
August 11, 2020

The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule this week that would give breakthrough medical devices national Medicare coverage on the same day they receive FDA approval for four years. The proposed rule, called Medicare Coverage of Innovative Technology (MCIT), would establish a Medicare coverage pathway that provides beneficiaries nationwide with faster access to new, innovative medical devices designated as ‘breakthrough’ by the Food and Drug Administration (FDA).

During the four year timeframe, CMS recommends that manufacturers develop additional evidence showing the applicability of their products to Medicare beneficiaries so they can apply for further coverage.

Before the MCIT, after a breakthrough technology receives FDA approval, an often lengthy and costly process for Medicare coverage begins. That period has been challenging for companies because innovators spent time and resources to achieve FDA approval, only to need to spend more time and money to acquire Medicare coverage. This lag time is not only costly but has also reduced access to innovative technologies by senior populations.

This proposed rule follows up on creating a pathway to Medicare coverage the same day as FDA market authorization for breakthrough devices. The proposal will be live from September 1, 2020 and open for comment till October 30, 2020. Additionally, the proposed rule would allow Medicare to cover eligible breakthrough devices the FDA has approved for use in 2019 or 2020.

What does it mean for you?

Organizations will need to understand the details of the breakthrough designation and how it applies to their innovation before proceeding. Moreover, what evidence needs to be generated in these four years to maintain coverage. The Alira Health team can help you understand how this designation applies to you, and how you can best leverage the proposed rule for your innovation.

For more information, please contact Deepak Sahu.

Click here to see the proposed rule from The Department of Health and Human Services.

Related news

Multimedia May 26, 2023
Webinar on Advancing Patient Engagement in the Medical Device / MedTech Industry
Engaging with patients, including their caregivers and advocates, is crucial during the planning and execution of clinical trials.
Medical Devices MedTech Patient Engagement
Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
Blog May 17, 2023
Introduction to Patient Engagement in MedTech in the U.S.
Check out these key takeaways from our Playbook for Patient Engagement in MedTech in the U.S. and access the playbook download.
MedTech Patient Engagement USA
Events April 26, 2023
MedTech Forum 2023
We are excited to share that we will be sponsoring and speaking at MedTech Forum 2023. The MedTech Forum is the largest health and medical technology industry conference in Europe and(...)
MedTech Real-World Evidence (RWE)
Publications April 25, 2023
Comprehensive Guide to the Content of Integrated Summaries of Efficacy and Safety (ISE/ISS)
Read this to discover the content of Integrated Summaries of Efficacy and Safety (ISE/ISS).
MedTech
Events April 18, 2023
MedTech Impact Gala 2023
We are excited to share that we will sponsor and speak at MedTech Impact Symposium 2023.  The Symposium is organized by Massachusetts Medical Device Industry Council (MassMEDIC) and(...)
Medical Devices MedTech
Events April 18, 2023
MedTech Impact Symposium 2023
We are excited to share that we will sponsor and speak at MedTech Impact Symposium 2023.  The Symposium is organized by Massachusetts Medical Device Industry Council (MassMEDIC) and(...)
Medical Devices MedTech
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.